Page 10 - Pharmaceuticals

GSK to invest $ 360 mn in 3 UK sites to augment pharma production

Investment will be made at Barnard Castle, Montrose and Ware sites for advanced manufacturing of new respiratory and biopharmaceuticals portfolio

Sun Pharma receives US FDA nod for cholesterol drug rosuvastatin

Rosuvastatin calcium tablets are therapeutic equivalents of IPR Pharmaceuticals Inc's Crestor

US FDA grants approval for Glenmark's rosuvastatin calcium tablet

As per the IMS health sales data for 12 month period ending May 2016, the rosuvastatin calcium tablets market achieved annual sales of approximately $ 6.78 billion

Dr Reddy's launches stomach ulcer treatment drug in US

The drug - omeprazole and sodium bicarbonate capsules - reportedly had US sales of approximately $ 306 million for the last twelve months ending in May 2016

Granules India buys 12.5% stake in USpharma

With this, Hyderabad based pharma company will have right of first refusal to market the select products which are under development by USpharma

Suven Life bags patents for CNS drug in India and South Africa

The company has received patents for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases

Sun Pharma rolls out anti-cancer Gemcitabine InfuSMART in Europe

It will launch Gemcitabine InfuSMART - a technology in which oncology products are developed in a ready-to-administer bag - in Netherlands, UK, Spain, Germany, Italy and France

US FDA approves Claris' anti-infective drug tobramycin injection

With this approval, the total addressable market size of the company's approved ANDAs is estimated to be a little above $ 300 million

Alembic receives US FDA approval for gout drug febuxostat

The approved product is generic equivalent of Takeda's Uloric, which has an estimated market size of $ 430 million for twelve months ending December 2015

Torrent Pharma buys Glochem API plant to aid backward integration

The acquisition will help Torrent Pharma in vertically integrating its abbreviated new drug application (ANDA) filings in the future

Siegfried's Nantong facility receives Chinese authorities nod

The production capacity of Siegfried's Nantong site, located in China's industrial park northwest of Shanghai, amounts to 350 cubic meters

Panacea Biotec launches diabetes drug teneligliptin

Tenepan (teneligliptin) is recommended to use in newly diagnosed patients and as an add-on therapy in patients uncontrolled on metformin or sulfonylurea therapy

Teva settles patent litigation with AstraZeneca related to diabetes drug

The settlement allows Teva to commercialise its generic version of AstraZeneca's Byetta (exenatide injection) in the US beginning October 15, 2017

Govt withdraws the Bill amending Drugs and Cosmetics Act

The government has decided to comprehensively review the existing law with objectives of facilitating the ease of doing business and enhancing the quality of Indian pharma products

Unichem receives approval for donepezil hydrochloride tablets

The product, which is generic version of Eisai's Aricept, is used to improve cognition and behaviour of people with Alzheimer's

Valeant Pharma to expand Canadian operations

While it will invest $15 million in Steinbach (Manitoba) facility, it will spend $ 12.5 million in Laval (Quebec) facility to increase local manufacturing and export volume

Zydus acquires two drugs from Teva to strengthen US portfolio

The total market size of the two acquired ANDAs (abbreviated new drug applications) is estimated at nearly $ 200 million

Ajanta Pharma launches of anti-dementia drug memantine HCl in US

The company has launched the drug, which is a generic version of Forest Laboratories' Namenda tablet, in two strengths - 5 mg & 10 mg tablets

Aspen buys AstraZeneca's anaesthetics in a $ 770-mn deal

As per the deal, Aspen will make an upfront payment of $520 mn and additional product sales-related payment of $250 mn to acquire rights to AstraZeneca's global anaesthetics portfolio

Lonza inks commercial manufacturing pact for Bluebird Bio's drugs

The agreement provides for the commercial production of Bluebird Bio's Lenti-D and LentiGlobin drug products at Lonza's dedicated production suites